THE EFFECTIVENESS OF EARLY ANTIVIRAL THERAPY IN COVID-19 SEVERITY

Authors

  • Alberto K x

Keywords:

COVID-19, SARS-CoV-2, antiviral therapy, remdesivir, early treatment, clinical outcomes

Abstract

The global outbreak of COVID-19 has led to a critical need for effective therapeutic strategies. Among these, early administration of antiviral agents such as remdesivir and molnupiravir has shown potential to reduce disease severity and improve clinical outcomes. This study investigates the clinical impact of initiating antiviral therapy during the early phase of SARS-CoV-2 infection, focusing on hospitalization rates, ICU admissions, and mortality.

Downloads

Download data is not yet available.

References

Gottlieb, R. L., Vaca, C. E., Paredes, R., et al. (2022). Early remdesivir to prevent progression to severe COVID-19 in outpatients. New England Journal of Medicine, 386(4), 305–315. https://doi.org/10.1056/NEJMoa2116846

Jayk Bernal, A., Gomes da Silva, M. M., Musungaie, D. B., et al. (2022). Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. New England Journal of Medicine, 386(6), 509–520. https://doi.org/10.1056/NEJMoa2116044

Hammond, J., Leister-Tebbe, H., Gardner, A., et al. (2022). Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine, 386(15), 1397–1408. https://doi.org/10.1056/NEJMoa2118542

WHO Solidarity Trial Consortium. (2022). Remdesivir and three other drugs for hospitalized patients with COVID-19: Final results of the WHO Solidarity randomized trial and updated meta-analyses. The Lancet, 399(10339), 1941–1953. https://doi.org/10.1016/S0140-6736(22)00519-0

Downloads

Published

2025-06-27

How to Cite

Alberto K. (2025). THE EFFECTIVENESS OF EARLY ANTIVIRAL THERAPY IN COVID-19 SEVERITY. Journal of Applied Science and Social Science, 15(06), 815–816. Retrieved from https://www.internationaljournal.co.in/index.php/jasass/article/view/1376

Issue

Vol. 15 No. 06 (2025): Volume 15 Issue 06

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in the Journal of Applied Science and Social Science (JASSS) is protected by copyright. Authors retain the copyright to their work, and grant JASSS the right to publish the work under a Creative Commons Attribution License (CC BY). This license allows others to distribute, remix, adapt, and build upon the work, even commercially, as long as they credit the author(s) for the original creation.